Cardiovascular · Beta-blockerRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Labetalol Hydrochloride by Epic Pharma

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 6:33:38 PM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of Epic Pharma's supplemental application for Labetalol Hydrochloride is a significant regulatory milestone that could alter competitive dynamics in the cardiovascular market. Portfolio teams should closely monitor this development to assess its implications for market positioning and potential partnerships. Regulatory context from FDA (FDA AP — LABETALOL HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this supplement on market dynamics and consider potential strategic partnerships or adjustments. The strongest clinical anchor is A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Beta-blocker, 8 regulatory and 2 competitive items passed relevance filtering for Epic Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals. This acceptance may enhance Epic Pharma's position in the cardiovascular market, potentially increasing competition with existing beta-blocker therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LABETALOL HYDROCHLORIDE (SUPPL) (FDA). Entity match (epic pharma). The acceptance of this supplemental application indicates a step towards potential approval, which could affect compliance and labeling for competing products.

Key Risks

Elevated medium regulatory exposure for Epic Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population) could weigh on Epic Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If approved, this supplement could enhance Epic Pharma's market share in the cardiovascular segment, impacting revenue streams for existing beta-blocker products.
Portfolio teams should assess the impact of this supplement on market dynamics and consider potential strategic partnerships or adjustments.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the review and any subsequent approval timelines from the FDA.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LABETALOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (epic pharma)
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA TA — VILOXAZINE HYDROCHLORIDE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — DOXEPIN HYDROCHLORIDE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — DEXMEDETOMIDINE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — SERTRALINE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — AMANTADINE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Epic Pharma
Labetalol Hydrochloride

Commercial impact

medium

If approved, this supplement could enhance Epic Pharma's market share in the cardiovascular segment, impacting revenue streams for existing beta-blocker products.

Regulatory impact

medium

The acceptance of this supplemental application indicates a step towards potential approval, which could affect compliance and labeling for competing products.

What to watch

Monitor the progress of the review and any subsequent approval timelines from the FDA.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.